Drug Profile
Vinorelbine liposomal - Taiwan Liposome Company
Alternative Names: Nanoliposomal vinorelbine - Taiwan Liposomal Company; TLC-178; Vinorelbine encapsulated liposome - TLCLatest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Taiwan Liposome Company
- Class Antineoplastics; Small molecules; Vinca alkaloids
- Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Lymphoma; Solid tumours
- No development reported Non-Hodgkin's lymphoma; Rhabdomyosarcoma
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Rhabdomyosarcoma in USA (Parenteral)
- 31 Dec 2020 Taiwan Liposome Company has patent protection covering the composition of matter of vinorelbine liposomal in Taiwan, China/Hong Kong, Japan, South Korea, Australia, USA and European countries, prior to December 2020
- 31 Dec 2020 Taiwan Liposome Company has patent protection for vinorelbine liposomal in USA, European and Asia markets, prior to December 2020